# A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer

> **NCT06283134** · PHASE1 · NOT_YET_RECRUITING · sponsor: **China Medical University, China** · enrollment: 60 (estimated)

## Conditions studied

- Colorectal Cancer Metastatic

## Interventions

- **BIOLOGICAL:** BioTTT001 hepatic artery infusion
- **DRUG:** toripalimab
- **DRUG:** regorafenib

## Key facts

- **NCT ID:** NCT06283134
- **Lead sponsor:** China Medical University, China
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03
- **Primary completion:** 2027-12-01
- **Final completion:** 2028-12-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-01-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06283134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06283134, "A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06283134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*